IntegraGen Inkomsten in het verleden
Verleden criteriumcontroles 0/6
IntegraGen has been growing earnings at an average annual rate of 48.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 13.4% per year.
Belangrijke informatie
48.1%
Groei van de winst
45.9%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 30.8% |
Inkomstengroei | 13.4% |
Rendement op eigen vermogen | -8.5% |
Nettomarge | -1.4% |
Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe IntegraGen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
31 Dec 23 | 13 | 0 | 5 | 0 |
30 Sep 23 | 13 | 0 | 5 | 0 |
30 Jun 23 | 13 | 0 | 5 | 0 |
31 Mar 23 | 13 | 0 | 5 | 0 |
31 Dec 22 | 13 | 0 | 5 | 0 |
30 Sep 22 | 13 | 0 | 3 | 0 |
30 Jun 22 | 13 | 0 | 0 | 0 |
31 Mar 22 | 12 | 0 | 0 | 0 |
31 Dec 21 | 11 | 0 | 0 | 0 |
30 Sep 21 | 10 | 0 | 3 | 0 |
30 Jun 21 | 9 | -1 | 6 | 0 |
31 Mar 21 | 9 | -1 | 6 | 0 |
31 Dec 20 | 9 | 0 | 6 | 0 |
30 Sep 20 | 9 | 0 | 6 | 0 |
30 Jun 20 | 9 | 0 | 6 | 0 |
31 Mar 20 | 9 | 0 | 6 | 0 |
31 Dec 19 | 8 | 0 | 6 | 0 |
30 Sep 19 | 8 | -1 | 4 | 0 |
30 Jun 19 | 7 | -1 | 3 | 0 |
31 Mar 19 | 7 | -1 | 3 | 0 |
31 Dec 18 | 7 | -1 | 3 | 0 |
30 Sep 18 | 7 | -1 | 3 | 0 |
30 Jun 18 | 7 | -1 | 3 | 0 |
31 Mar 18 | 7 | -1 | 3 | 0 |
31 Dec 17 | 7 | -1 | 3 | 0 |
30 Sep 17 | 6 | -1 | 4 | 0 |
30 Jun 17 | 7 | -1 | 3 | 0 |
31 Mar 17 | 6 | -1 | 3 | 0 |
31 Dec 16 | 6 | -2 | 3 | 0 |
30 Sep 16 | 6 | -2 | 3 | 0 |
30 Jun 16 | 6 | -2 | 3 | 0 |
31 Mar 16 | 6 | -2 | 3 | 0 |
31 Dec 15 | 6 | -2 | 3 | 0 |
30 Sep 15 | 6 | -1 | 3 | 0 |
30 Jun 15 | 6 | -1 | 3 | 0 |
31 Mar 15 | 6 | -1 | 3 | 0 |
31 Dec 14 | 6 | -1 | 3 | 0 |
30 Sep 14 | 6 | -1 | 3 | 0 |
30 Jun 14 | 5 | -2 | 3 | 0 |
31 Mar 14 | 5 | -2 | 3 | 0 |
31 Dec 13 | 5 | -3 | 3 | 0 |
Kwaliteitswinsten: ALINT is currently unprofitable.
Groeiende winstmarge: ALINT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ALINT is unprofitable, but has reduced losses over the past 5 years at a rate of 48.1% per year.
Versnelling van de groei: Unable to compare ALINT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ALINT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: ALINT has a negative Return on Equity (-8.52%), as it is currently unprofitable.